Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma

BACKGROUND: Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this antigen on immature plasma cells may limit the efficacy of this modality and facili...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Liqing, Zhang, Jian, Li, Minghao, Xu, Nan, Qi, Wei, Tan, Jingwen, Lou, Xiaoyan, Yu, Zhou, Sun, Juanjuan, Wang, Zhenkun, Fu, Chengcheng, Tang, Xiaowen, Dai, Haiping, Chen, Jia, Wu, Depei, Yu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222432/
https://www.ncbi.nlm.nih.gov/pubmed/32435496
http://dx.doi.org/10.1186/s40364-020-00192-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222432/
https://www.ncbi.nlm.nih.gov/pubmed/32435496
http://dx.doi.org/10.1186/s40364-020-00192-6

Ejemplares similares